WARNING

Blincyto (blinatumomab) is a medication used to treat a certain type of leukemia called B-cell precursor acute lymphoblastic leukemia (ALL). Like all medications, Blincyto comes with potential risks. Some of the risks associated with taking Blincyto include:

• Cytokine release syndrome (CRS): This is a common side effect of Blincyto treatment and can cause symptoms such as fever, headache, nausea, fatigue, and low blood pressure. In severe cases, CRS can be life-threatening.
• Neurological toxicities: Blincyto can cause neurological side effects such as confusion, seizures, and difficulty speaking. These side effects can be serious and may require treatment or discontinuation of the medication.
• Infections: Blincyto can weaken the immune system, making patients more susceptible to infections. It’s important for patients taking Blincyto to take precautions to avoid infections and to seek medical attention if they develop signs of an infection.
• Tumor lysis syndrome (TLS): Blincyto treatment can cause the rapid breakdown of cancer cells, leading to TLS. This can result in complications such as kidney failure, abnormal heart rhythms, and seizures.
• Hypersensitivity reactions: Some patients may experience allergic reactions to Blincyto, which can range from mild to severe.
• Other side effects: Other common side effects of Blincyto include fatigue, headache, fever, and decreased appetite.

It’s important for patients to discuss the potential risks and benefits of Blincyto treatment with their healthcare provider before starting treatment. Additionally, patients should be closely monitored for side effects during treatment.

Why is this medication prescribed?

Blincyto (blinatumomab) is prescribed for the treatment of a certain type of leukemia called B-cell precursor acute lymphoblastic leukemia (ALL). It is specifically indicated for use in patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor ALL. This means it’s used when the leukemia has come back after treatment (relapsed) or has not responded to previous treatment (refractory), and the leukemia cells do not have a specific genetic abnormality known as the Philadelphia chromosome.

How should this medicine be used?

Blincyto is a type of immunotherapy called a bispecific T-cell engager (BiTE) antibody. It works by helping the body’s immune system recognize and attack leukemia cells. Blincyto works by binding to both leukemia cells and T cells (a type of white blood cell involved in the immune response), bringing them close together and allowing the T cells to kill the leukemia cells.

Blincyto is administered as an intravenous infusion (injected into a vein). The dosing and schedule can vary depending on the individual patient and their response to treatment. Typically, Blincyto is given continuously over a 28-day treatment cycle, followed by a 14-day treatment-free period. This cycle may be repeated until the leukemia responds to treatment or until unacceptable side effects occur.

The exact dose and schedule of Blincyto should be determined by a healthcare provider experienced in the use of cancer medications. Patients should receive proper instruction on how to prepare and administer Blincyto and should be closely monitored for side effects during treatment.

Other uses for this medicine

Blincyto (blinatumomab) is primarily used for the treatment of a certain type of leukemia called B-cell precursor acute lymphoblastic leukemia (ALL). However, it may also have potential uses in other types of leukemia or lymphoma in clinical trials or off-label use. It’s important to note that any use of Blincyto beyond its approved indication should be done under the supervision of a healthcare provider experienced in the use of this medication.

What special precautions should I follow?

As for special precautions when using Blincyto, here are some key points to consider:

• Monitoring: Patients receiving Blincyto should be closely monitored by their healthcare provider for signs of side effects or complications. This may include regular blood tests to monitor for changes in blood cell counts and other laboratory parameters.
• Infections: Blincyto can weaken the immune system, making patients more susceptible to infections. Patients should take precautions to avoid exposure to infectious agents and should promptly report any signs or symptoms of infection to their healthcare provider.
• Neurological toxicities: Blincyto can cause neurological side effects such as confusion, seizures, and difficulty speaking. Patients should be monitored for these symptoms, and treatment may need to be adjusted or discontinued if neurological toxicity occurs.
• Cytokine release syndrome (CRS): This is a common side effect of Blincyto treatment and can cause symptoms such as fever, headache, nausea, fatigue, and low blood pressure. Healthcare providers should be prepared to manage CRS, which may involve supportive care and, in severe cases, interruption or discontinuation of Blincyto treatment.
• Hypersensitivity reactions: Some patients may experience allergic reactions to Blincyto, which can range from mild to severe. Patients should be monitored for signs of hypersensitivity reactions, and treatment should be discontinued if necessary.
• Pregnancy and breastfeeding: The safety of Blincyto during pregnancy and breastfeeding is not well established. Women of childbearing age should use effective contraception during treatment with Blincyto, and breastfeeding should be avoided.
• Liver and kidney function: Blincyto may affect liver and kidney function. Patients with pre-existing liver or kidney conditions should be monitored closely during treatment.

It’s important for patients to discuss any concerns or questions about Blincyto with their healthcare provider before starting treatment.

What special dietary instructions should I follow?

Regarding special dietary instructions, there are no specific dietary restrictions associated with Blincyto. However, it’s important to maintain a balanced and nutritious diet to support your overall health and well-being during treatment.

What should I do if I forget a dose?

If you forget a dose of Blincyto, contact your healthcare provider or treatment team as soon as possible for guidance. They will advise you on the best course of action, which may include rescheduling the missed dose or adjusting your treatment schedule. It’s important not to double up on doses without medical supervision.

What side effects can this medication cause?

Blincyto (blinatumomab) can cause various side effects, ranging from mild to severe. Some common side effects include:

• Cytokine release syndrome (CRS): This is a common side effect of Blincyto treatment and can cause symptoms such as fever, chills, headache, nausea, fatigue, and low blood pressure. In severe cases, CRS can lead to organ dysfunction and be life-threatening.
• Neurological toxicities: Blincyto can cause neurological side effects such as confusion, seizures, tremors, and difficulty speaking. These symptoms may require medical intervention and could lead to treatment interruption or discontinuation.
• Infections: Blincyto can weaken the immune system, making patients more susceptible to infections. Common infections associated with Blincyto treatment include respiratory infections, urinary tract infections, and sepsis.
• Tumor lysis syndrome (TLS): Blincyto treatment can lead to the rapid breakdown of cancer cells, resulting in TLS. This can cause complications such as kidney failure, abnormal heart rhythms, and electrolyte imbalances.
• Hypersensitivity reactions: Some patients may experience allergic reactions to Blincyto, which can range from mild (e.g., rash, itching) to severe (e.g., anaphylaxis). Immediate medical attention is necessary if an allergic reaction occurs.
• Other side effects: Additional side effects of Blincyto may include fatigue, headache, diarrhea, vomiting, decreased appetite, anemia, and thrombocytopenia (low platelet count).

It’s essential for patients receiving Blincyto to be closely monitored for side effects by their healthcare provider. Prompt reporting of any new or worsening symptoms is crucial for appropriate management and adjustment of treatment as needed.

What should I know about storage and disposal of this medication?

Storage and Disposal of Blincyto:

• Storage: Blincyto is typically supplied as a powder for injection, which needs to be reconstituted with a diluent before use. Once reconstituted, the solution should be stored in the refrigerator at a temperature between 36°F to 46°F (2°C to 8°C) and protected from light. Do not freeze Blincyto or expose it to direct sunlight. Store the medication in its original carton to protect it from light.
• Disposal: Unused portions of Blincyto and any materials used in the administration of the medication (e.g., syringes, needles) should be disposed of properly according to local regulations. Your healthcare provider or pharmacist can provide guidance on how to safely dispose of these materials.

In case of emergency/overdose

In the event of an emergency or overdose with Blincyto, seek immediate medical attention or contact your local poison control center. There is no specific antidote for Blincyto overdose, so treatment will focus on managing symptoms and providing supportive care as needed.

What other information should I know?

• Other Information: Before starting Blincyto treatment, inform your healthcare provider about any allergies you have, as well as any other medications, supplements, or herbal products you are taking. Discuss your medical history, including any pre-existing conditions such as infections, neurological disorders, or liver/kidney problems.
• Pregnancy and breastfeeding: It’s important to discuss the risks and benefits of Blincyto treatment if you are pregnant, planning to become pregnant, or breastfeeding. Blincyto may cause harm to a developing fetus, and breastfeeding should be avoided during treatment.
• Monitoring: During Blincyto treatment, your healthcare provider will monitor you closely for side effects and assess your response to therapy. Be sure to attend all scheduled appointments and report any new or worsening symptoms promptly.
• Travel: If you need to travel while receiving Blincyto treatment, plan ahead to ensure you have an adequate supply of medication and proper storage conditions during transit. Follow any special instructions provided by your healthcare provider or treatment team.

By following these guidelines and staying informed about your treatment, you can help ensure the safe and effective use of Blincyto.